Aggressive NK-cell leukemia: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 25: | Line 25: | ||
*The table below demonstrates the [[Immunophenotyping|immunophenotype]] for [[Patient|patients]] with aggressive NK-cell leukemia.<ref name="cha2">[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10389582&query_hl=10&itool=pubmed_ExternalLink] | *The table below demonstrates the [[Immunophenotyping|immunophenotype]] for [[Patient|patients]] with aggressive NK-cell leukemia.<ref name="cha2">[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10389582&query_hl=10&itool=pubmed_ExternalLink] | ||
Chan JK. "Natural killer cell neoplasms." '''Anat Pathol'''. 1998;3:77-145. PMID 10389582</ref> | Chan JK. "Natural killer cell neoplasms." '''Anat Pathol'''. 1998;3:77-145. PMID 10389582</ref> | ||
::{| border="1" cellpadding="5" cellspacing="0" | ::{| border="1" cellpadding="5" cellspacing="0" | ||
|- | |- | ||
| Line 65: | Line 64: | ||
:*[[Myelofibrosis]] | :*[[Myelofibrosis]] | ||
*[[Prognosis]] is generally poor, and the [[median]] [[survival rate]] of [[patients]] with aggressive NK-cell leukemia is few months. | *[[Prognosis]] is generally poor, and the [[median]] [[survival rate]] of [[patients]] with aggressive NK-cell leukemia is few months. | ||
== Diagnosis == | |||
=== Staging === | === Staging === | ||
The table below shows the staging system for aggressive NK-cell leukemia according to the Ann Arbor staging system.<ref name="ListerCrowther1989">{{cite journal|last1=Lister|first1=T A|last2=Crowther|first2=D|last3=Sutcliffe|first3=S B|last4=Glatstein|first4=E|last5=Canellos|first5=G P|last6=Young|first6=R C|last7=Rosenberg|first7=S A|last8=Coltman|first8=C A|last9=Tubiana|first9=M|title=Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.|journal=Journal of Clinical Oncology|volume=7|issue=11|year=1989|pages=1630–1636|issn=0732-183X|doi=10.1200/JCO.1989.7.11.1630}}</ref> | The table below shows the staging system for aggressive NK-cell leukemia according to the Ann Arbor [[staging]] system.<ref name="ListerCrowther1989">{{cite journal|last1=Lister|first1=T A|last2=Crowther|first2=D|last3=Sutcliffe|first3=S B|last4=Glatstein|first4=E|last5=Canellos|first5=G P|last6=Young|first6=R C|last7=Rosenberg|first7=S A|last8=Coltman|first8=C A|last9=Tubiana|first9=M|title=Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.|journal=Journal of Clinical Oncology|volume=7|issue=11|year=1989|pages=1630–1636|issn=0732-183X|doi=10.1200/JCO.1989.7.11.1630}}</ref> | ||
{| class="wikitable" | {| class="wikitable" | ||
|+ | |+ | ||
Revision as of 21:07, 21 October 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2] Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[3] Maria Fernanda Villarreal, M.D. [4]
Synonyms and keywords: ANKL
Overview
Aggressive NK-cell leukemia is a disease with an aggressive, systemic proliferation of natural killer cells (NK cells) and a rapidly declining clinical course. There is no classification system for aggressive NK-cell leukemia. The pathogenesis of aggressive NK-cell leukemia is characterized by the proliferation of natural killer cells. Aggressive NK-cell leukemia is very uncommon, and is most commonly seen among middle aged adults. The most common risk factors in the development of aggressive NK-cell leukemia is the Epstein-Barr virus (EBV) infection. The majority of patients with aggressive NK-cell leukemia are symptomatic at diagnosis. Early clinical features include fatigue, night sweats, and fever. Physical examination among patients with aggressive NK-cell leukemia may be remarkable for hepatosplenomegaly. Aggressive NK-cell leukemia may also be diagnosed using bone marrow biopsy, findings of which can include extensive marrow replacement by leukemic cells and reactive histiocytes displaying hemophagocytosis. The mainstay of therapy for aggressive NK-cell leukemia is anthracycline-containing chemotherapy.
Historical Perspective
- In 1986, Dr. Fernandez and his colleagues reported the first case of aggressive NK-cell leukemia.[1]
Classification
- There is no classification system for aggressive NK-cell leukemia.
- This disorder is classified as a large granular lymphocyte (LGL) leukemia according to third WHO classification.[2]
Pathophysiology
- The pathogenesis of aggressive NK-cell leukemia is characterized by the aggressive, systemic proliferation of natural killer cells.
- The mutation in oncogene p53 has been associated with the development of aggressive NK-cell leukemia.
- On gross pathology, characteristic findings of aggressive NK-cell leukemia include:
- No remarkable findings
- On microscopic histopathological analysis, characteristic findings of aggressive NK-cell leukemia include:[3]
- The table below demonstrates the immunophenotype for patients with aggressive NK-cell leukemia.[3]
Causes
- There are no established causes for aggressive NK-cell leukemia.
Differentiating Aggressive NK-cell Leukemia from Other Diseases
- Aggressive NK-cell leukemia must be differentiated from other diseases that cause fever, fatigue, and lymphadenopathy such as:
- Aggressive NK-cell leukemia should also be differentiated from other lymphoprolierative disorders originating from natural killer cells including extranodal NK/T cell lymphoma, nasal type (NKTCL) and chronic lymphoproliferative disorders of NK-cells (CLPD-NK).[4]
Epidemiology and Demographics
- Aggressive NK-cell leukemia is a rare disorder.[5][6]
- Aggressive NK-cell leukemia is more commonly observed among young adults with median age of 42 years old.
- Aggressive NK-cell leukemia affects men more frequently than women.
- Aggressive NK-cell leukemia usually affects individuals of the Asian race.[7]
Risk Factors
Common risk factors in the development of aggressive NK-cell leukemia include Epstein-Barr virus (EBV) infection[5][8]
Screening
- There is insufficient evidence to recommend routine screening for aggressive NK-cell leukemia.
Natural History, Complications, and Prognosis
- The majority of patients with aggressive NK-cell leukemia are symptomatic at the time of diagnosis.[7]
- Early clinical features include fatigue, night sweats, and fever.
- If left untreated, patients with aggressive NK-cell leukemia may progress to develop recurrent infections.
- Common complications of aggressive NK-cell leukemia, include:[9]
- Prognosis is generally poor, and the median survival rate of patients with aggressive NK-cell leukemia is few months.
Diagnosis
Staging
The table below shows the staging system for aggressive NK-cell leukemia according to the Ann Arbor staging system.[10]
| Stage | Staging Criteria |
| Stage I |
|
| Stage II |
|
| Stage III |
|
| Stage IV
|
|
Symptoms
- Fever
- Swelling in the lymph nodes in the neck
- Night sweats
- Persistent fatigue
- Loss of appetite
- Weight loss
- Nausea
- Vomiting
- Yellow discoloration of the sclera
- Enlarged liver or spleen
Physical Examination
- Patients with aggressive NK-cell leukemia usually appear icteric and malnourished.[9][7]
- Physical examination may be remarkable for:
Laboratory Findings
Peripheral Blood Smear
- Large granular lymphocyte (LGL)
- Fine or coarse azurophilic granules and nucleoli of varying prominence
- Nuclei may be irregular and hyperchromatic
- There are no cytogenetic abnormalities specific to ANKL.
- However, following cytogenetic abnormalites have been reported more frequently among patients with aggressive NK-cell leukemia.
- chromosomes 6q and 11q [14]
- Complete blood count (CBC) may show cytopenias.[15]
Electrocardiogram
- There are no ECG findings associated with aggressive NK-cell leukemia.
X-ray
There are no x-ray findings associated with aggressive NK-cell leukemia.
Echocardiography or Ultrasound
- There are no echocardiography/ultrasound findings associated with aggressive NK-cell leukemia.
CT scan
- There are no CT scan findings associated with aggressive NK-cell leukemia.
MRI
- There are no MRI findings associated with aggressive NK-cell leukemia.
Other Imaging Findings
- There are no other imaging findings associated with aggressive NK-cell leukemia.
Other Diagnostic Studies
- Aggressive NK-cell leukemia may also be diagnosed using bone marrow biopsy.
- Findings on bone marrow biopsy, include:
- Extensive marrow replacement by leukemic cells
- Reactive histiocytes displaying hemophagocytosis
Treatment
Medical Therapy
- The mainstay of therapy for aggressive NK-cell leukemia is anthracycline-containing chemotherapy.[16]
- L-asparaginase containing chemotherapy regimen followed by allogeneic stem cell transplantation shows to slightly prolong life, but relapse is almost assured.[17]
- Other novel treatments may include pralatrexate.
- None of the aforementioned treatment regimens have been curatieve.
- Allogenic bone marrow transplantation has been reported successful in some cases.[18]
Surgery
- Surgery is not recommended among patients with aggressive NK-cell leukemia.
Primary Prevention
- There are no primary preventive measures available for aggressive NK-cell leukemia.
Secondary Prevention
- There are no secondary preventive measures available for aggressive NK-cell leukemia.
References
- ↑ Fernandez LA, Pope B, Lee C, Zayed E (April 1986). "Aggressive natural killer cell leukemia in an adult with establishment of an NK cell line". Blood. 67 (4): 925–30. PMID 3955237.
- ↑ Ishida, Fumihiro (2018). "Aggressive NK-Cell Leukemia". Frontiers in Pediatrics. 6. doi:10.3389/fped.2018.00292. ISSN 2296-2360.
- ↑ 3.0 3.1 [1] Chan JK. "Natural killer cell neoplasms." Anat Pathol. 1998;3:77-145. PMID 10389582
- ↑ Swerdlow, Steven (2017). WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer. ISBN 9789283244943.
- ↑ 5.0 5.1 Suzuki, R; Suzumiya, J; Nakamura, S; Aoki, S; Notoya, A; Ozaki, S; Gondo, H; Hino, N; Mori, H; Sugimori, H; Kawa, K; Oshimi, K (2004). "Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells". Leukemia. 18 (4): 763–770. doi:10.1038/sj.leu.2403262. ISSN 0887-6924.
- ↑ Tang YT, Wang D, Luo H, Xiao M, Zhou HS, Liu D, Ling SP, Wang N, Hu XL, Luo Y, Mao X, Ao QL, Huang J, Zhang W, Sheng LS, Zhu LJ, Shang Z, Gao LL, Zhang PL, Zhou M, Zhou KG, Qiu LG, Liu QF, Zhang HY, Li JY, Jin J, Fu L, Zhao WL, Chen JP, Du X, Huang G, Wang QF, Zhou JF, Huang L (December 2017). "Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes". Blood Cancer J. 7 (12): 660. doi:10.1038/s41408-017-0021-z. PMC 5802497. PMID 29263371.
- ↑ 7.0 7.1 7.2 Lima, Margarida (2013). "Aggressive mature natural killer cell neoplasms: from epidemiology to diagnosis". Orphanet Journal of Rare Diseases. 8 (1): 95. doi:10.1186/1750-1172-8-95. ISSN 1750-1172.
- ↑ Kawa-Ha, K; Ishihara, S; Ninomiya, T; Yumura-Yagi, K; Hara, J; Murayama, F; Tawa, A; Hirai, K (1989). "CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA". Journal of Clinical Investigation. 84 (1): 51–55. doi:10.1172/JCI114168. ISSN 0021-9738.
- ↑ 9.0 9.1 Li, Chunrui; Tian, Ye; Wang, Jue; Zhu, Li; Huang, Liang; Wang, Na; Xu, Danmei; Cao, Yang; Li, Jianyong; Zhou, Jianfeng (2014). "Abnormal immunophenotype provides a key diagnostic marker: a report of 29 cases of de novo aggressive natural killer cell leukemia". Translational Research. 163 (6): 565–577. doi:10.1016/j.trsl.2014.01.010. ISSN 1931-5244.
- ↑ Lister, T A; Crowther, D; Sutcliffe, S B; Glatstein, E; Canellos, G P; Young, R C; Rosenberg, S A; Coltman, C A; Tubiana, M (1989). "Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting". Journal of Clinical Oncology. 7 (11): 1630–1636. doi:10.1200/JCO.1989.7.11.1630. ISSN 0732-183X.
- ↑ Song SY, Kim WS, Ko YH, Kim K, Lee MH, Park K (December 2002). "Aggressive natural killer cell leukemia: clinical features and treatment outcome". Haematologica. 87 (12): 1343–5. PMID 12495907.
- ↑ Sheridan W, Winton EF, Chan WC, Gordon DS, Vogler WR, Phillips C, Bongiovanni KF, Waldmann TA (November 1988). "Leukemia of non-T lineage natural killer cells". Blood. 72 (5): 1701–7. PMID 2846089.
- ↑ Nazarullah, Alia; Don, Michelle; Linhares, Yuliya; Alkan, Serhan; Huang, Qin (2016). "Aggressive NK-cell leukemia: A rare entity with diagnostic and therapeutic challenge". Human Pathology: Case Reports. 4: 32–37. doi:10.1016/j.ehpc.2015.08.001. ISSN 2214-3300.
- ↑ Wong, K. F.; Zhang, Y. M.; Chan, J. K. C. (2009). "Cytogenetic Abnormalities in Natural Killer Cell LymphomaLeukaemia - Is There a Consistent Pattern?". Leukemia & Lymphoma. 34 (3–4): 241–250. doi:10.3109/10428199909050949. ISSN 1042-8194.
- ↑ Loughran TP (July 1993). "Clonal diseases of large granular lymphocytes". Blood. 82 (1): 1–14. PMID 8324214.
- ↑ Ishida F (2018). "Aggressive NK-Cell Leukemia". Front Pediatr. 6: 292. doi:10.3389/fped.2018.00292. PMC 6191480. PMID 30364049.
- ↑ Ishida F, Ko YH, Kim WS, Suzumiya J, Isobe Y, Oshimi K, Nakamura S, Suzuki R (June 2012). "Aggressive natural killer cell leukemia: therapeutic potential of L-asparaginase and allogeneic hematopoietic stem cell transplantation". Cancer Sci. 103 (6): 1079–83. doi:10.1111/j.1349-7006.2012.02251.x. PMID 22360679.
- ↑ Takami A, Nakao S, Yachie A, Kasahara Y, Okumura H, Miura Y, Sugimori N, Zeng W, Wang H, Kotani T, Shiobara S, Matsuda T (June 1998). "Successful treatment of Epstein-Barr virus-associated natural killer cell large granular lymphocytic leukaemia using allogeneic peripheral blood stem cell transplantation". Bone Marrow Transplant. 21 (12): 1279–82. doi:10.1038/sj.bmt.1701262. PMID 9674865.